Search research articles
Contact Us
Filters
Showing results (151-160 of 163) with videos related to
Page
of 17
Sort By:
Oncogene
|
September 26, 2023
MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex
Wangjie Jiang, Xiao Yang, Kuangheng Shi, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
February 22, 2024
PIN1 promotes the metastasis of cholangiocarcinoma cells by RACK1-mediated phosphorylation of ANXA2
Yuming Wang, Yiwei Liu, Hairong Chen, et al.
Nature Communications
|
June 1, 2022
The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers
Yaodong Zhang, Zijian Ma, Changxian Li, et al.
Frontiers in Oncology
|
June 17, 2022
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
Xiaofeng Chen, Wei Li, Xiaofeng Wu, et al.
Journal of Hepatology
|
May 24, 2016
14-3-3η is a novel growth-promoting and angiogenic factor in hepatocellular carcinoma
Jian Shen, Fei Jiang, Ye Yang, et al.
Trials
|
August 25, 2019
Regional lymphadenectomy vs. extended lymphadenectomy for hilar cholangiocarcinoma (Relay-HC trial): study protocol for a prospective, multicenter, randomized controlled trial
Min He, Xinsen Xu, Hao Feng, et al.
Hepatology (Baltimore, Md.)
|
June 29, 2020
M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α<sub>M</sub> β<sub>2</sub> Integrin to Tumor Cells
Jindao Wu, Wen Gao, Qiyun Tang, et al.
Journal for Immunotherapy of Cancer
|
November 19, 2021
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Xiaofeng Chen, Deqiang Wang, Jing Liu, et al.
Journal for Immunotherapy of Cancer
|
November 11, 2020
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2022
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 163) with videos related to
Sort By:
Page
of 17
Oncogene
|
September 26, 2023
MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex
Wangjie Jiang, Xiao Yang, Kuangheng Shi, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
February 22, 2024
PIN1 promotes the metastasis of cholangiocarcinoma cells by RACK1-mediated phosphorylation of ANXA2
Yuming Wang, Yiwei Liu, Hairong Chen, et al.
Nature Communications
|
June 1, 2022
The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers
Yaodong Zhang, Zijian Ma, Changxian Li, et al.
Frontiers in Oncology
|
June 17, 2022
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
Xiaofeng Chen, Wei Li, Xiaofeng Wu, et al.
Journal of Hepatology
|
May 24, 2016
14-3-3η is a novel growth-promoting and angiogenic factor in hepatocellular carcinoma
Jian Shen, Fei Jiang, Ye Yang, et al.
Trials
|
August 25, 2019
Regional lymphadenectomy vs. extended lymphadenectomy for hilar cholangiocarcinoma (Relay-HC trial): study protocol for a prospective, multicenter, randomized controlled trial
Min He, Xinsen Xu, Hao Feng, et al.
Hepatology (Baltimore, Md.)
|
June 29, 2020
M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α<sub>M</sub> β<sub>2</sub> Integrin to Tumor Cells
Jindao Wu, Wen Gao, Qiyun Tang, et al.
Journal for Immunotherapy of Cancer
|
November 19, 2021
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Xiaofeng Chen, Deqiang Wang, Jing Liu, et al.
Journal for Immunotherapy of Cancer
|
November 11, 2020
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Xiaofeng Chen, Xiaofeng Wu, Hao Wu, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2022
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, et al.
Page
of 17